This mutation is present in approximately 25% of IDH-mutant astrocytomas; it is significantly less prevalent in other cancer types, where, although also considered a hotspot mutation, it occurs in only 2.7% of cases [24,25,26]. This evidence concerns the gene IDH2 and cancer.